Prior Sunitinib Treatment May Prolong Progression-Free Survival with Subsequent TKI Use

Share this content:

(ChemotherapyAdvisor) – First-line treatment with sunitinib for 9 months or more may be associated with a longer progression-free survival (PFS) in patients who receive subsequent VEGFR tyrosine kinase inhibitors, results of Phase 3 AXIS trial data in second-line metastatic renal cell carcinoma (RCC) comparing axitinib and sorafenib presented during the 2012 Genitourinary Cancers Symposium have found.

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, and colleagues evaluated the effect of prior sunitinib treatment duration and axitinib dose titration on subsequent axitinib efficacy within the AXIS trial, in which axitinib significantly prolonged median PFS, 6.7 vs 4.7 months (HR=0.665; P<0.0001).

A total of 53.7% of patients (n=194) in the axitinib arm and 53.9% in the sorafenib arm (n=195) received prior treatment with sunitinib. Median PFS for prior sunitinib treatment duration ≥6 months and <6 months was 4.8 vs. 4.6 months for axitinib and 4.6 vs. 2.9 months for sorafenib. For duration of prior sunitinib ≥9 months and <9 months, median PFS was 6.3 vs. 4.5 months for axitinib and 4.6 vs 2.9 months for sorafenib. Median PFS for patients receiving at least one total daily axitinib dose >10 mg (dose-titrated group; n=132) was 6.6 months vs. 8.3 months for those receiving axitinib ≤10 mg (n=227).

The FDA approved axitinib (Inlyta), Pfizer Inc, for the treatment of advanced RCC after failure of one prior systemic therapy on January 27, 2012.

The 2012 Genitourinary Cancers Symposium is sponsored by the American Society of Clinical Oncology, American Society for Radiation Oncology, and the Society of Urologic Oncology.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs